- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model NEW YORK ( TheStreet) -- Pharmacyclics Incorporated (Nasdaq: PCYC) hit a new 52-week high Wednesday as it is currently trading at $60.76, above its previous 52-week high of $60.05 with 165,851 shares traded as of 10 a.m. ET. Average volume has been 1.3 million shares over the past 30 days. Pharmacyclics has a market cap of $3.89 billion and is part of the health care sector and drugs industry. Shares are up 282% year to date as of the close of trading on Tuesday. Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The company has a P/E ratio of 262.5, below the average drugs industry P/E ratio of 281.9 and above the S&P 500 P/E ratio of 17.7.